{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:48:05Z","timestamp":1782492485225,"version":"3.54.5"},"reference-count":17,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"unspecified","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Aethlon Medical Australia PTY LTD"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,12,17]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immunotherapy with anti-programmed cell death protein 1 (anti-PD-1) inhibitors has revolutionised the treatment of many solid tumours, however, only 30\u201340% of patients will have a lasting clinical response. Tumour-derived extracellular vesicles (EVs) have been implicated in the spread of solid tumours and resistance to these agents. A lectin-affinity plasmapheresis device called the Hemopurifier (HP) has been developed and shown to remove EVs in vitro and in patients. We hypothesise that the treatment of patients who are not improving on a regimen that includes an anti-PD-1 agent will be safe, decrease EV concentrations and improve antitumour T cell activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This safety, feasibility and dose-finding study is designed in a 3+3 safety study design with three treatment cohorts. Participants who are determined not to be responding to a regimen that includes an anti-PD-1 agent will be assigned to receive either one, two or three (HP) treatments over a 1-week period prior to their next scheduled dose of anti-PD-1 antibody. Advancement from one cohort to the next will be determined by a Data and Safety Monitoring Board. Data collection will include adverse events, safety labs, EV concentrations and T cell measurements, repeat imaging and survival status.<\/jats:p>\n                    <jats:p>The primary outcome of the study will be the safety of the HP in this population, with additional endpoints to include the kinetics of EV removal and rebound following HP treatment, in addition to the effects on T cell numbers and activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The clinical protocol and amendment to the study protocol have been approved by the Central Adelaide Local Health Network Human Research Ethics Committee for Royal Adelaide Hospital (reference number 2024\/HRE00031) and the Bellberry Human Research Ethics Committee for Pindara Private Hospital and Genesis Care\/Royal North Shore Hospital (reference number 2024-06-724-A-6). The Therapeutic Goods Administration has been notified. The clinical trial is listed on the Australian New Zealand Clinical Trials Registry. Informed Consent is obtained from all participants prior to any protocol procedures being performed. Results of the main trial and each of the secondary endpoints will be submitted for publication in a peer-reviewed journal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>Australia New Zealand registration number ACTRN12624000732583.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-102581","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T01:10:36Z","timestamp":1767661836000},"page":"e102581","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Hemopurifier device in patients with solid tumours who have stable or progressive disease while on a treatment that includes pembrolizumab or nivolumab: protocol for an Australian safety, feasibility and dose-finding study"],"prefix":"10.1136","volume":"16","author":[{"given":"Michael P","family":"Brown","sequence":"first","affiliation":[{"name":"Centre for Cancer Biology, SA Pathology and University of South Australia, Royal Adelaide Hospital, Adelaide, South Australia, Australia"},{"name":"University of Adelaide\u2014North Terrace Campus, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Matos","sequence":"additional","affiliation":[{"name":"Oncology, Pindara Private Hospital, Benowa, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5817-1222","authenticated-orcid":false,"given":"Stephen","family":"Clarke","sequence":"additional","affiliation":[{"name":"Kolling Institute of Medical Research, Saint Leonards, New South Wales, Australia"},{"name":"Medical Oncology, Royal North Shore Hospital, Saint Leonards, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0342-8179","authenticated-orcid":false,"given":"P Toby","family":"Coates","sequence":"additional","affiliation":[{"name":"University of Adelaide\u2014North Terrace Campus, Adelaide, South Australia, Australia"},{"name":"Central and Northern Adelaide Renal and Transplantation Service (CNARTS), Royal Adelaide Hospital, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7167-6495","authenticated-orcid":false,"given":"Carol","family":"Pollock","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, Royal North Shore Hospital, Saint Leonards, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagadeesh","family":"Kurtkoti","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Gold Coast University Hospital, Gold Coast, Queensland, Australia"},{"name":"Griffith University School of Medicine and Dentistry, Gold Coast, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Grau","sequence":"additional","affiliation":[{"name":"Vascular Immunology Unit: Infection, Immunity and Inflammation Research Theme, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Edinburg","sequence":"additional","affiliation":[{"name":"ReSQ Clinical Research, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Bloesch","sequence":"additional","affiliation":[{"name":"Aethlon Medical, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalia","family":"de Necochea Campion","sequence":"additional","affiliation":[{"name":"Aethlon Medical, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nyan Y","family":"Khin","sequence":"additional","affiliation":[{"name":"H&A Clinical Pty, Burwood, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Shin","sequence":"additional","affiliation":[{"name":"Oncology, Loma Linda University, Loma Linda, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0773-2816","authenticated-orcid":false,"given":"Steven P","family":"LaRosa","sequence":"additional","affiliation":[{"name":"Aethlon Medical, San Diego, California, USA"},{"name":"Aethlon Medical Australia Pty, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"2026062609051181000_16.1.e102581.1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.0423","article-title":"Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs","volume":"3","author":"Haslam","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2026062609051181000_16.1.e102581.2","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000065"},{"key":"2026062609051181000_16.1.e102581.3","unstructured":"Liu A . With Keytruda leading the way, Merck tallies 80-plus potential oncology approvals by 2028. 2022 Available: https:\/\/www.fiercepharma.com\/pharma\/keytruda-leading-way-merck-counts-over-80-possible-oncology-drug-approvals-2028"},{"key":"2026062609051181000_16.1.e102581.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"2026062609051181000_16.1.e102581.5","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.bbcan.2019.04.004","article-title":"Exosomes in cancer development, metastasis, and immunity","volume":"1871","author":"Zhang","year":"2019","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"2026062609051181000_16.1.e102581.6","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001698","article-title":"Mechanisms underlying low-clinical responses to PD-1\/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1","volume":"9","author":"Yin","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026062609051181000_16.1.e102581.7","doi-asserted-by":"crossref","DOI":"10.1080\/20013078.2019.1710899","article-title":"Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients","volume":"9","author":"Cordonnier","year":"2020","journal-title":"J Extracell Vesicles"},{"key":"2026062609051181000_16.1.e102581.8","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-022-02379-1","article-title":"Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer","volume":"41","author":"de Miguel-Perez","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"2026062609051181000_16.1.e102581.9","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202103245","article-title":"Sulfisoxazole Elicits Robust Antitumour Immune Response Along with Immune Checkpoint Therapy by Inhibiting Exosomal PD-L1","volume":"9","author":"Shin","year":"2022","journal-title":"Adv Sci (Weinh)"},{"key":"2026062609051181000_16.1.e102581.10","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s12276-022-00856-3","article-title":"Targeted inhibition of tumor-derived exosomes as a novel therapeutic option for cancer","volume":"54","author":"Li","year":"2022","journal-title":"Exp Mol Med"},{"key":"2026062609051181000_16.1.e102581.11","doi-asserted-by":"crossref","unstructured":"Amundson DE , Shah US , de Necochea-Campion R , et al . Removal of COVID-19 Spike Protein, Whole Virus, Exosomes, and Exosomal MicroRNAs by the Hemopurifier Lectin-Affinity Cartridge in Critically Ill Patients With COVID-19 Infection. Front Med 2016;8. doi:10.3389\/fmed.2021.744141","DOI":"10.3389\/fmed.2021.744141"},{"key":"2026062609051181000_16.1.e102581.12","doi-asserted-by":"publisher","DOI":"10.1006\/jmbi.1996.0532"},{"key":"2026062609051181000_16.1.e102581.13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ab.2019.06.001","article-title":"Application of high-mannose-type glycan-specific lectin from Oscillatoria Agardhii for affinity isolation of tumor-derived extracellular vesicles","volume":"580","author":"Yamamoto","year":"2019","journal-title":"Anal Biochem"},{"key":"2026062609051181000_16.1.e102581.14","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-11-108","article-title":"Interaction and uptake of exosomes by ovarian cancer cells","volume":"11","author":"Escrevente","year":"2011","journal-title":"BMC Cancer"},{"key":"2026062609051181000_16.1.e102581.15","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2020-4509"},{"key":"2026062609051181000_16.1.e102581.16","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001113","article-title":"Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles","volume":"8","author":"Orme","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026062609051181000_16.1.e102581.17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1449"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-102581","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:05:26Z","timestamp":1782489926000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-102581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,5]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/bmjopen-2025-102581"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-102581","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}